Gout is a common disorder of uric acid metabolism that is very common in patients with chronic kidney disease (CKD). Metabolic syndrome is a serious health condition associated with a higher cardiovascular disease (CVD) risk at all stages of CKD. This lecture discusses hyperuricaemia, metabolic syndrome, and CKD, and the role of urate-lowering therapy, including the selective non-purine xanthine oxidase (XO) inhibitor, febuxostat, in the treatment of hyperuricaemia.
Prof Austin Stack is Foundation Chair of Medicine at the Graduate Entry Medical School, University of Limerick and consultant nephrologist at University Hospital Limerick, Ireland. His research interests focus on risk factors, complications, and treatment strategies for chronic kidney disease (CKD) and acute kidney injury (AKI), including anaemia, iron deficiency and hyperuricaemia, and their links with cardiovascular disease. He has published extensively in these areas and is principal investigator for several CKD and AKI studies.
Associate Prof Jimmy Teo is a professor at National University of Singapore and Senior Consultant and Head of the Division of Nephrology, Department of Medicine, National University Hospital. He is also Research Director, and Associate Program Director of the Peritoneal Dialysis Program. His research focuses on the link between retinal blood vessel morphology, kidney function, and biomarkers of kidney injury.